Log in
NASDAQ:LPCN

Lipocine Stock Forecast, Price & News

$1.20
-0.06 (-4.76 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.15
Now: $1.20
$1.25
50-Day Range
$1.21
MA: $1.41
$1.61
52-Week Range
$0.30
Now: $1.20
$2.96
Volume1.03 million shs
Average Volume2.23 million shs
Market Capitalization$78.82 million
P/E RatioN/A
Dividend YieldN/A
Beta0.49
Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Read More
Lipocine logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383
Employees10

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$170,000.00
Book Value$0.25 per share

Profitability

Net Income$-13,010,000.00

Miscellaneous

Market Cap$78.82 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$1.20
-0.06 (-4.76 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lipocine (NASDAQ:LPCN) Frequently Asked Questions

How has Lipocine's stock been impacted by COVID-19?

Lipocine's stock was trading at $0.4511 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LPCN shares have increased by 166.0% and is now trading at $1.20.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Lipocine?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Lipocine
.

When is Lipocine's next earnings date?

Lipocine is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Lipocine
.

How were Lipocine's earnings last quarter?

Lipocine Inc (NASDAQ:LPCN) released its earnings results on Thursday, August, 6th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.06.
View Lipocine's earnings history
.

What price target have analysts set for LPCN?

2 Wall Street analysts have issued 1-year price targets for Lipocine's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Lipocine's share price to reach $3.00 in the next year. This suggests a possible upside of 150.0% from the stock's current price.
View analysts' price targets for Lipocine
.

Are investors shorting Lipocine?

Lipocine saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 4,270,000 shares, an increase of 31.0% from the September 15th total of 3,260,000 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.
View Lipocine's Short Interest
.

Who are some of Lipocine's key competitors?

What other stocks do shareholders of Lipocine own?

Who are Lipocine's key executives?

Lipocine's management team includes the following people:
  • Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 62)
  • Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 51)
  • Logan Morse, VP of Sales, Marketing & Operations (Age 49)
  • Nachiappan Chidambaram, VP of Product Devel. (Age 50)
  • Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 88)

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $1.20.

How big of a company is Lipocine?

Lipocine has a market capitalization of $78.82 million and generates $170,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,010,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Lipocine employs 10 workers across the globe.

What is Lipocine's official website?

The official website for Lipocine is www.lipocine.com.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.